Our Founders

Our studio was forged in 2021 by – Max, Michel, and Sriram – united by their shared goal to re-establish discovery as the basis for the next generation of immunotherapies.

With their deep knowledge of immunobiology and their impressive track record of discovering and developing multiple, multibillion-dollar immunotherapies, they have positioned Foundery to increase the efficiency and effectiveness of the pre-clinical R&D process.

They aim to preserve the innovative culture of biotech and bridge the translational gap by providing leading academic scientists with exclusive access to best-in-class technology platforms and the necessary R&D infrastructure to transform their discoveries into breakthrough therapies.

Photo of Max Krummel

Matthew “Max” Krummel, Ph.D.

  • Discovered and patented Checkpoint blockade therapy, anti-CTLA-4, in 1995, which had more than $2B in Sales
  • Founded Pionyr, anti-TREM1/2, in 2016, which resulted in a $1.7B deal with Gilead
  • Discovered Immune Archetypes in Cancer and COVID
  • Professor at UCSF since 2001; Robert E. Smith Endowed Chair in Experimental Pathology; Chair of the ImmunoX Initiative
View full bio
Michel Streuli, Ph.D.

Michel Streuli, Ph.D.

  • Drove early development of multiple immunotherapies, including IntronA and Keytruda, which resulted in combined sales of more than $14B
  • 20 years of industry experience across Organon, Schering-Plough, Merck, Gilead, and Pionyr
  • 10 years of academic experience including professorships at Harvard Medical School and Dana-Farber Cancer Institute faculty
View full bio

Venkataraman “Sriram”, Ph.D.

  • Guided pre-clinical pharmacology for Keytruda
  • Led Pionyr's non-clinical program for PY314
  • More than 15 years of experience in immunology and immuno-oncology R&D as well as strategy development at Schering Plough, Merck, Gilead, and Pionyr
  • Expertise in small molecule and biologics development for immuno-oncology
View full bio

Our Founders

Foundery was founded and is run by a storied team with exclusive access to best-in-class technologies, including the “immune archetype” platform and has an outstanding R&D track-record across multiple target areas and diseases.  Foundery’s deep knowledge of immune archetypes provides exceptional insight into the translatability of rodent biology for human disease (often an underlying cause of poor clinical success rates), as well as informing dose selection, pharmacodynamic markers, and the patient cohorts who are most likely to benefit from the therapies (the right medicine for the right patient).

Max Krummel

Max Krummel, Ph.D.

Matthew Krummel, Ph.D. is the Chair of the UCSF ImmunoX Initiative (immunox.ucsf.edu) and holds the Robert E. Smith Endowed Chair in Pathology. His lab (krummellab.com) specializes in using real-time imaging to launch and test hypotheses related to how the immune system processes information and makes decisions. Key recent discoveries have included determining features of T cell membrane biology and motility that govern how they efficiently survey for antigens as well as the discovery of archetypal collections of immune systems in cancer, notably those involving networks of cells built around stimulatory dendritic cells. His work spans scales from membrane organization, to cell biology, to entire immune systems. He received his Ph.D. at the University of California, Berkeley and did postdoctoral studies at Stanford University.

Dr. Krummel drives collaborative science: he founded a microscopy ‘collaboratory’ at UCSF which unites ‘shared’ technical personnel and he developed a novel industry consortium-funded project (immunoprofiler.org) which unites studies of over 15 cancer indications to understand the biology of individual patients. Together with other UCSF faculty, he founded the ImmunoX initiative, a radical collaboration platform focused on methods and data sharing as a means to accelerate discovery and cures. His initiative also emphasizes public outreach and interaction as a means to disseminate the value of science. Dr. Krummel’s work has led to multiple clinical advances including discovering anti-CTLA-4 ‘checkpoint blockade’ drugs (over 100,000 patients treated) and new next-generation immunotherapies through Pionyr Immunotherapeutics, and now Foundery Innovations, ventures that he co-founded and which have extensive academic-industry collaboration. The aim of all of his research is to understand and apply the immune system to improve human health.

Michel Streuli, Ph.D.

Michel Streuli, Ph.D.

Michel, Foundery Innovations CEO, has extensive scientific and executive administrative experience in the pharmaceutical and biotech industries, leading drug development from discovery through the early clinical stage, with a focus on therapies for cancer, chronic viral, autoimmune, and inflammatory diseases. He has over thirty years of leadership, innovation, team-building, collaboration, fundraising, and management experience in biologics and small molecule drug development, and over twenty-five years of experience directing basic and applied research at several companies, including Pionyr Immunotherapeutics, Gilead Sciences, Merck Research Laboratories, Schering-Plough Research Institute (acquired by Merck, Inc), Organon BioSciences (acquired by Schering-Plough), and ImmunoGen Inc., as well as a faculty member for ten years at the Dana-Farber Cancer Institute and Harvard Medical School. He played key roles in advancing multiple novel and biosimilar biologics into clinical development, including the first FDA approved immunotherapy, IFN-alpha2/IntronA®, and the anti-PD-1 immuno-oncology drug Keytruda®. He received his Ph.D. degree from the University of Zurich, Switzerland, and his postdoctoral training in the Division of Tumor Biology at the Dana-Farber Cancer Institute.


Venkataraman “Sriram”, Ph.D.

Sriram is an accomplished researcher with nearly 15 years of biopharmaceutical research experience developing biological and small molecule therapeutics against tumor immunotherapy targets. Prior to joining Max and Michel in starting Foundery, Sriram was at Pionyr Immunotherapeutics for over four years from the early stages. At Pionyr, Sriram played a key role in helping build the research team, leading the operational move from the incubator space to an independent facility, and serve as nonclinical lead for PY314 program. Sriram was also the author, editor, and coordinator of all regulatory filings including pre-IND and IND. Prior to Pionyr, Sriram was at Gilead Sciences for close to three years. Sriram established and successively led several immuno-oncology programs at Gilead Sciences and Merck. At Merck Research Laboratories (formerly the Schering-Plough Biopharma prior to its acquisition by Merck), Sriram also served as the cross-site pharmacology lead for all immuno-oncology programs, including the anti-PD-1 antibody Keytruda. Sriram received his Ph.D. degree in Biochemistry and Immunology from the University of Madras, India, and completed his post-doctoral training in immunology at the Indiana University School of Medicine.

Scientific & Business Advisory Boards

Scientific Advisory Board

Our Scientific Advisory Board is an amalgam of cutting-edge academics and industry veterans, collectively serving to provide wide-ranging scientific and technical expertise and external scientific review of our R&D activities.

Business Advisory Board

Our Business Advisory Board is comprised of prominent investors and business leaders who provide strategic guidance for our portfolio companies.

Contact Us

Interested in learning more? We're looking forward to hearing from you.